Cara Therapeutics Announces 1-for-3 Reverse Stock Split in Connection with the Proposed Merger with Tvardi Therapeutics

Core Points - Cara Therapeutics, Inc. has announced a 1-for-3 reverse stock split of its outstanding shares of common stock [1] - The company's common stock will begin trading under the new name "Tvardi Therapeutics, Inc." and the new symbol "TVRD" following the merger with Tvard Therapeutics, Inc. [2] - The reverse stock split was approved by stockholders and will reduce the number of outstanding shares from approximately 4.6 million to approximately 1.5 million [3][4] Company Overview - Tvardi Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing oral small molecule therapies targeting STAT3 for fibrosis-driven diseases [7] - Cara Therapeutics is a biopharmaceutical company that has developed an IV formulation of difelikefalin for treating moderate-to-severe pruritus associated with advanced kidney disease [8]